While prostate cancer is becoming more prevalent among middle-aged and elderly men in China, clinical practice still faces considerable challenges due to the lack of unified guidelines and high-level evidence on several aspects of patient care.
PF-08046054 by Pfizer for Solid Tumor: Likelihood of Approval
PF-08046054 is under clinical development by Pfizer and currently in Phase I for Solid Tumor.